Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsRob Eno - CEOTim Cruickshank - CFOLarry Holub ...

The 3.9-kilometre extension of the tramline in Bratislava's Petržalka borough is nearing completion. Mayor Matúš Vallo has pledged that trams will begin operating on the new section by the end of May.

In the study, the mean difference in ECG intervals and amplitude between the company’s ECG and the standard 12-lead ECG was assessed. Findings highlight a 93.4% diagnostic agreement, suggesting that ...

As per the reports the device will launch on May 15 worldwide, and leaks suggest the new Watch 5 Pro will arrive with a more advanced ECG sensor and a range of new health features. If true ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam’s synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing ...

The VALID-ECG study compared HeartBeam’s synthesized 12-lead ECG to the traditional standard 12-lead ECG, focusing on mean differences in ECG intervals and amplitudes that are crucial for assessing ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG. Data from the study showed a ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam’s synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in ...